Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans may predict who is most at risk for dangerous low blood sugar

NCT ID NCT04207619

Diagnosis Sponsor: Pennington Biomedical Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether a brain imaging measurement can predict how strongly the body reacts to low blood sugar. The study enrolls healthy adults aged 18 to 40 with a body mass index between 20 and 30. Participants undergo two procedures: a brain scan to measure glial acetate metabolism and a hyperinsulinemic-hypoglycemic clamp to trigger and track the body's response to low blood sugar. The goal is to see if the brain measurement correlates with the hormonal response to hypoglycemia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperinsulinemic-hypoglycemic clamp
What this could lead to
If the biomarker works, doctors could one day identify people with diabetes who are most vulnerable to dangerous low blood sugar and tailor their treatment to prevent it.
What could go wrong
This is a small, early-stage study in healthy adults, not people with diabetes. The biomarker may not predict hypoglycemia risk reliably, and the specialized brain scans are not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2020

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male or female * Ages 18-40 years * BMI between 20 kg/m2 and 30 kg/m2 (±0.5 kg/m2 will be accepted) * Medically cleared for participation in the study Exclusion Criteria: * Contraindication to MRI * Consume \>10 alcoholic drinks/week * History of chronic smoking or have quit less than 10 years ago * History of clinically diagnosed diabetes or a fasting blood glucose \>126 mg/dL * Average screening blood pressure \>140/90 mmHg * History of cardiovascular disease * Pregnant, planning to become pregnant, or breastfeeding * Use of medications affecting glucose metabolism, e.g., benzodiazepines, thiazide diuretics, cortisone, and prednisone. * Use of beta-adrenergic antagonists. * Based on the investigative team's clinical judgement, a subject may not be appropriate for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus hypoglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes Hypoglycemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pennington Biomedical Research Center

    Baton Rouge, Louisiana, 70808-4124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.